08.20.15
Cyberonics Inc. and Sorin S.p.A., who announced a merger in February, are making progress on the regulatory fronts.
The companies’ registration statement on Form S-4 for LivaNova plc, the proposed name for the newly formed company, filed in April and amended three times, was declared effective by the U.S. Securities and Exchange Commission, thus paving the way for convening the special meeting of Cyberonics stockholders to consider and vote on the transaction. The meeting will take place on Sept. 22.
The companies currently expect that the merger, which remains subject to Cyberonics stockholder approval and satisfaction of other customary closing conditions, will close in the fourth calendar quarter of 2015.
Cyberonics’ core expertise is in neuromodulation technology. The company makes the VNS Therapy system, which is U.S. Food and Drug Administration-approved for the treatment of medically refractory epilepsy and treatment-resistant depression. The company is based in Houston, texas.
Sorin makes medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. The company’s headquarters are in Milan, Italy.
The companies’ registration statement on Form S-4 for LivaNova plc, the proposed name for the newly formed company, filed in April and amended three times, was declared effective by the U.S. Securities and Exchange Commission, thus paving the way for convening the special meeting of Cyberonics stockholders to consider and vote on the transaction. The meeting will take place on Sept. 22.
The companies currently expect that the merger, which remains subject to Cyberonics stockholder approval and satisfaction of other customary closing conditions, will close in the fourth calendar quarter of 2015.
Cyberonics’ core expertise is in neuromodulation technology. The company makes the VNS Therapy system, which is U.S. Food and Drug Administration-approved for the treatment of medically refractory epilepsy and treatment-resistant depression. The company is based in Houston, texas.
Sorin makes medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. The company’s headquarters are in Milan, Italy.